Anti-Parkinson's disease drugs and pharmacogenetic considerations

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 7, 2013, Pages 859-874

  Agúndez, José A G ^a,b   García Martín, Elena ^a,b   Alonso Navarro, Hortensia ^c   Jiménez Jiménez, Félix Javier ^c  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b Red de Investigación de Reacciones Adversas A Alergenos y Fármacos RIRAAF   (Spain)

^c Hospital Universitario del Sureste de Madrid   (Spain)

Author keywords

Adverse drug reactions; Biomarkers; Parkinson's disease; Pharmacogenetics; Pharmacogenomics

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BENSERAZIDE; BENZATROPINE; BIPERIDEN; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; ENTACAPONE; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL;

ABDOMINAL PAIN; ABNORMAL DREAMING; AGGRESSION; AMINO ACID SUBSTITUTION; AMNESIA; AUDITORY HALLUCINATION; BLOOD BRAIN BARRIER; BLURRED VISION; COGNITIVE DEFECT; COMA; COMPULSION; CONFUSION; CONGESTIVE HEART FAILURE; CONSTIPATION; DELIRIUM; DELUSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRY NOSE; DRY THROAT; DYSKINESIA; DYSPHORIA; EDEMA; ENZYME INDUCTION; EUPHORIA; FIRST PASS EFFECT; FLUSHING; GENE FREQUENCY; GENETIC VARIABILITY; HALLUCINATION; HAPLOTYPE; HEART ARRHYTHMIA; HEART MUSCLE FIBROSIS; HUMAN; HYPERSEXUALITY; HYPOTENSION; IMPULSIVENESS; INSOMNIA; IRRITABILITY; LEUKOPENIA; LIBIDO; LIVEDO RETICULARIS; LIVER TOXICITY; MANIA; MOTOR DYSFUNCTION; NAUSEA; NAUSEA AND VOMITING; NERVOUSNESS; NIGHTMARE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PANIC; PARANOIA; PARESTHESIA; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PERIPHERAL EDEMA; PHARMACOGENETICS; PLEURAL FIBROSIS; PSYCHOSIS; RAYNAUD PHENOMENON; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; SUICIDAL IDEATION; SWEATING; THINKING IMPAIRMENT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINE COLOR; URINE RETENTION; VASOCONSTRICTION; VASOSPASM; VISUAL HALLUCINATION; VOMITING; XEROSTOMIA;

ARYL HYDROCARBON HYDROXYLASES; BENZOTHIAZOLES; BENZTROPINE; BROMOCRIPTINE; CATECHOLS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; ERGOLINES; GENETIC MARKERS; HUMANS; INDANS; INDOLES; LEVODOPA; LISURIDE; NITRILES; PARKINSON DISEASE; PERGOLIDE; PHARMACOGENETICS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; REPRODUCIBILITY OF RESULTS; SELEGILINE;

EID: 84879217322     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.789018     Document Type: Review

References (100)

1. CPIC. Clinical Pharmacogenetics Implementation Consortium. 2013. Available from: http://www. pharmgkb.org/page/cpic [Last accessed 31 January 2013]. This link contains relevant information on gene/drugs pairs.
2. Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S2-41.
3. Nation RL, Triggs EJ, Vine J. Metabolism and urinary excretion of benzhexol in humans. Xenobiotica 1978;8(3):165-9 (Pubitemid 8305661)
4. Capka V, Xu Y, Chen YH. Stereoselective determination of trihexyphenidyl in human serum by LC-ESI-MS. J Pharm Biomed Anal 1999;21(3):507-17 (Pubitemid 29512216)
5. He H, McKay G, Midha KK. Phase I and II metabolites of benztropine in rat urine and bile. Xenobiotica 1995;25(8):857-72
6. Burke RE, Fahn S. Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol 1985;18(1):35-40 (Pubitemid 15025411)
7. Cheung WK, Stravinski SS, Engel SI, et al. Pharmacokinetic evaluation of a sustained-release formulation of trihexyphenidyl in healthy volunteers. J Pharm Sci 1988;77(9):748-50 (Pubitemid 19030306)
8. DrugBank. Open Data Drug & Drug Target Database. 2013. Available from: http://www.drugbank.ca/[Last accesed 31 January 2013] . Updated drug database.
9. PharmGkb. The Pharmacogenomics Knowledgebase. 2013. Available from: http://www.pharmgkb.org [Last accesed 31 January 2013] . Updated database on pharmacogenetics implications for combinations of genes and drugs.
10. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013;9(2):106-18
11. Pomara N, Willoughby LM, Wesnes K, et al. Increased anticholinergic challenge-induced memory impairment associated with the APOE-epsilon4 allele in the elderly: a controlled pilot study. Neuropsychopharmacology 2004;29(2):403-9 (Pubitemid 38175157)
12. Hollmann M, Brode E, Greger G, et al. Biperiden effects and plasma levels in volunteers. Eur J Clin Pharmacol 1984;27(5):619-21 (Pubitemid 15176773)
13. Grimaldi R, Perucca E, Ruberto G, et al. Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects. Eur J Clin Pharmacol 1986;29(6):735-7 (Pubitemid 16155752)
14. Othman AA, Syed SA, Newman AH, et al. Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther 2007;320(1):344-53 (Pubitemid 46025749)
15. Zanger UM, Turpeinen M, Klein K, et al. Functional pharmacogenetics/ genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008;392(6):1093-108
16. P450. Drug Interaction Table. 2013. Available from: http://medicine. iupui.edu/clinpharm/ddis/table.aspx [Last accessed 31 January 2013].
17. Benitez J, Ladero JM, Jimenez-Jimenez FJ, et al. Oxidative polymorphism of debrisoquine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53(4):289-92 (Pubitemid 20152007)
18. Agundez JA, Del Barrio J, Padro T, et al. Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology. Front Pharmacol 2012;3:2
19. U.S.-FDA. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labels. 2013. Available from: http://www.fda.gov/drugs/ scienceresearch/researchareas/pharmacogenetics/ucm083378.htm [Last accessed 31 January 2013]
20. CYP2C19. Allele nomenclature. 2013. Available from: http://www. cypalleles.ki.se/cyp2c19.htm [Last accessed 31 January 2013].
21. CYP2D6. Allele nomenclature. 2013. Available from: http://www. cypalleles.ki.se/cyp2d6.htm [Last accessed 31 January 2013] . List of variant alleles and their functional consequences.
22. 1000 Genomes. A Deep Catalog of Human Genetic Variation. 2013. Available from: http://browser.1000genomes.org/index.html [Last accessed 31 January 2013]
23. Koppel C, Tenczer J. A revision of the metabolic disposition of amantadine. Biomed Mass Spectrom 1985;12(9):499-501 (Pubitemid 15237239)
24. Bras AP, Hoff HR, Aoki FY, et al. Amantadine acetylation may be effected by acetyltransferases other than NAT1 or NAT2. Can J Physiol Pharmacol 1998;76(7-8):701-6 (Pubitemid 29106619)
25. Bras AP, Janne J, Porter CW, et al. Spermidine/spermine n(1)-acetyltransferase catalyzes amantadine acetylation. Drug Metab Dispos 2001;29(5):676-80 (Pubitemid 32374568)
26. Bialecka M, Kurzawski M, Klodowska-Duda G, et al. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet Genomics 2008;18(9):815-21
27. Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989;39(11 Suppl 2):25-38 (Pubitemid 20020578)
28. Bartholini G, Burkard WP, Pletscher A. Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature 1967;215(5103):852-3
29. Marsden CD, Parkes JD, Rees JE. A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet 1973;2(7844):1459-62
30. Markham C, Diamond SG, Treciokas LJ. Carbidopa in Parkinson disease and in nausea and vomiting of levodopa. Arch Neurol 1974;31(2):128-33
31. Vickers S, Stuart EK, Bianchine JR, et al. Metabolism of carbidopa (1-(-)-alphahydrazino-3,4-dihydroxy-alphamethylhydrocinnamic acid monohydrate), an aromatic amino acid decarboxylase inhibitor, in the rat, rhesus monkey, and man. Drug Metab Dispos 1974;2(1):9-22
32. Sagar KA, Smyth MR. Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. Analyst 2000;125(3):439-45 (Pubitemid 30179314)
33. Cesar IC, Byrro RM, Santana ESCFF, et al. Development and validation of a high-performance liquid chromatography-electrospray ionization-MS/MS method for the simultaneous quantitation of levodopa and carbidopa in human plasma. J Mass spectrom 2011;46(9):943-8
34. Durso R, Evans JE, Josephs E, et al. Variable absorption of carbidopa affects both peripheral and central levodopa metabolism. J Clin Pharmacol 2000;40(8):854-60
35. Brod LS, Aldred JL, Nutt JG. Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease. Mov Disord 2012;27(6):750-3
36. Schwartz DE, Jordan JC, Ziegler WH. Pharmacokinetics of the decarboxylase inhibitor benserazide in man; its tissue distribution in the rat. Eur J Clin Pharmacol 1974;7(1):39-45
37. Jorga KM, Larsen JP, Beiske A, et al. The effect of tolcapone on the pharmacokinetics of benserazide. Eur J Neurol 1999;6(2):211-19 (Pubitemid 29141903)
38. Breitling LP, Muller H, Illig T, et al. Dopamine-related genes and spontaneous smoking cessation in ever-heavy smokers. Pharmacogenomics 2011;12(8):1099-106
39. Maurer G, Schreier E, Delaborde S, et al. Fate and disposition of bromocriptine in animals and man. II: absorption, elimination and metabolism. Eur J Drug Metab Pharmacokinet 1983;8(1):51-62 (Pubitemid 13119979)
40. Isin EM, Guengerich FP. Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4. J Biol Chem 2006;281(14):9127-36 (Pubitemid 43864626)
41. Matsubayashi K, Matsumoto H, Fukui Y. Contribution of cytochrome P450 3A pathway to bromocriptine metabolism and effects of ferrous iron and hypoxia-re-oxygenation on its elimination in the perfused rat liver. J Pharm Pharmacol 1997;49(5):551-7 (Pubitemid 27229481)
42. Humpel M, Sostarek D, Gieschen H, et al. Studies on the biotransformation of lonazolac, bromerguride, lisuride and terguride in laboratory animals and their hepatocytes. Xenobiotica 1989;19(4):361-77 (Pubitemid 19108255)
43. Bychkov E, Ahmed MR, Dalby KN, et al. Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J Neurochem 2007;102(3):699-711 (Pubitemid 47057295)
44. Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 1997;25(10):1211-14 (Pubitemid 27446593)
45. Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006;28(8):1065-78 (Pubitemid 44374749)
46. Andreotti AC, Pianezzola E, Persiani S, et al. Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers. J Clin Endocrinol Metab 1995;80(3):841-5
47. Nakatsuka A, Nagai M, Yabe H, et al. Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease. J Pharmacol Sci 2006;100(1):59-64 (Pubitemid 43161615)
48. Garcia-Martin E, Martinez C, Pizarro RM, et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002;71(3):196-204 (Pubitemid 34271123)
49. CYP3A4. Allele nomenclature. 2013. Available from: http://www. cypalleles.ki.se/cyp3a4.htm [Last accessed 31 January 2013].
50. Klein K, Zanger UM. Pharmacogenomics of cytochrome P450 3A4 (CYP3A4): recent progress towards the "missing heritability" problem. Front Genet 2013;4:12. Comprehensive review on CYP3A4.
51. Nelson MV, Berchou RC, Kareti D, et al. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clin Pharmacol Ther 1990;47(6):694-7 (Pubitemid 20207326)
52. Lu WJ, Huang K, Lai ML, et al. Erythromycin alters the pharmacokinetics of bromocriptine by inhibition of organic anion transporting polypeptide C-mediated uptake. Clin Pharmacol Ther 2006;80(4):421-2 (Pubitemid 44465885)
53. Christensen J, Dupont E, ∅Stergaard K. Cabergoline plasma concentration is increased during concomitant treatment with itraconazole. Mov Disord 2002;17(6):1360-2 (Pubitemid 36041356)
54. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000;39(4):243-54
55. CYP1A2. Allele nomenclature. 2013. Available from: http://www. cypalleles.ki.se/cyp1a2.htm [Last accessed 31 January 2013].
56. Zhou SF, Wang B, Yang LP, et al. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010;42(2):268-354
57. Wright CE, Sisson TL, Ichhpurani AK, et al. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997;37(6):520-5 (Pubitemid 27265653)
58. Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 2009;37(10):2055-60
59. Cawello W, Ahrweiler S, Sulowicz W, et al. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function. Br J Clin Pharmacol 2012;73(1):46-54
60. LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology 2004;62(6 Suppl 4):S8-11
61. Neef C, van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 1999;37(3):257-71 (Pubitemid 29452757)
62. Kalinderi K, Fidani L, Katsarou Z, et al. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease. Int J Clin Pract 2011;65(12):1289-94
63. Rieck M, Schumacher-Schuh AF, Altmann V, et al. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. Pharmacogenomics 2012;13(15):1701-10
64. Strong JA, Dalvi A, Revilla FJ, et al. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2006;21(5):654-9 (Pubitemid 43792746)
65. Arbouw ME, Movig KL, Egberts TC, et al. Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease. Eur J Clin Pharmacol 2009;65(12):1245-51
66. Liu YZ, Tang BS, Yan XX, et al. Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients. Eur J Clin Pharmacol 2009;65(7):679-83
67. McGuire V, Van Den Eeden SK, Tanner CM, et al. Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium. J Neurol Sci 2011;307(1-2):22-9
68. Garcia-Martin E, Martinez C, Alonso-Navarro H, et al. Dopamine receptor D3 (DRD3) genotype and allelic variants and risk for essential tremor. Mov Disord 2009;24(13):1910-15
69. Jimenez-Jimenez FJ, Alonso-Navarro H, Martinez C, et al. Dopamine receptor D3 (DRD3) gene rs6280 variant and risk for restless legs syndrome. Sleep Med 2013; Epub ahead of print
70. Kamada T, Chow T, Hiroi T, et al. Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes. Drug Metab Pharmacokinet 2002;17(3):199-206
71. Benetton SA, Fang C, Yang YO, et al. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet 2007;22(2):78-87
72. Slawson MH, Taccogno JL, Foltz RL, et al. Quantitative analysis of selegiline and three metabolites (N-desmethylselegiline, methamphetamine, and amphetamine) in human plasma by high-performance liquid chromatography- atmospheric pressure chemical ionization-tandem mass spectrometry. J Anal Toxicol 2002;26(7):430-7 (Pubitemid 36206777)
73. Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet 1997;33(2):91-102 (Pubitemid 27336950)
74. CYP2B6. Allele nomenclature. 2013. Available from: http://www. cypalleles.ki.se/cyp2b6.htm [Last accessed 31 January 2013].
75. Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet 2013;4:24 . Comprehensive review on CYP2B6.
76. Restrepo JG, Martinez C, Garcia-Agundez A, et al. Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles. Pharmacogenet Genomics 2011;21(12):773-8
77. Laine K, Anttila M, Nyman L, et al. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. Eur J Clin Pharmacol 2001;57(2):137-42 (Pubitemid 32449134)
78. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79(1):103-13 (Pubitemid 43069582)
79. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361(13):1268-78
80. Guay DR. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother 2006;4(4):330-46 (Pubitemid 46222213)
81. Bialecka M, Drozdzik M, Klodowska-Duda G, et al. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. Acta Neurol Scand 2004;110(4):260-6 (Pubitemid 39274062)
82. Heikkinen H, Saraheimo M, Antila S, et al. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. Eur J Clin Pharmacol 2001;56(11):821-6 (Pubitemid 33788554)
83. Keranen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994;46(2):151-7 (Pubitemid 24101334)
84. Gordin A, Kaakkola S, Teravainen H. Clinical advantages of COMT inhibition with entacapone-a review. J Neural Transm 2004;111(10-11):1343-63 (Pubitemid 39468395)
85. Lautala P, Ethell BT, Taskinen J, et al. The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 2000;28(11):1385-9
86. Borges N. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. Expert Opin Drug Saf 2005;4(1):69-73
87. Andrade RJ, Agundez JA, Lucena MI, et al. Pharmacogenomics in drug induced liver injury. Curr Drug Metab 2009;10(9):956-70
88. Stocchi F, De Pandis MF. Utility of tolcapone in fluctuating Parkinson's disease. Clin Interv Aging 2006;1(4):317-25
89. Jorga KM, Kroodsma JM, Fotteler B, et al. Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites. Clin Pharmacol Ther 1998;63(6):646-54 (Pubitemid 28327892)
90. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4(6):489-99 (Pubitemid 40861991)
91. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol Omethyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995;34(13):4202-10
92. Corvol JC, Bonnet C, Charbonnier-Beaupel F, et al. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. Ann Neurol 2011;69(1):111-18
93. Chong DJ, Suchowersky O, Szumlanski C, et al. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Clin Neuropharmacol 2000;23(3):143-8 (Pubitemid 30395375)
94. Garcia-Martin E, Martinez C, Ladero JM, et al. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10(1):29-40
95. Garcia-Martin E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab 2008;9(6):487-97 (Pubitemid 352034203)
96. Ledesma MC, Agundez JA. Identification of subtypes of CYP2D gene rearrangements among carriers of CYP2D6 gene deletion and duplication. Clin Chem 2005;51(6):939-43 (Pubitemid 40740872)
97. Agundez JA, Golka K, Martinez C, et al. Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008;54(8):1390-4
98. Ruiz JD, Martinez C, Anderson K, et al. The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype. PloS One 2012;7(9):e44629
99. Houle D, Govindaraju DR, Omholt S. Phenomics: the next challenge. Nat Rev Genet 2010;11(12):855-66
100. Agundez JA, Garcia-Martin E, Martinez C. Genetically based impairment in CYP2C8-and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol 2009;5(6):607-20